Evidence map›Paper›PMID 28282489›Full record

ArticleInvestigative ophthalmology & visual science2017

Systematic Functional Testing of Rare Variants: Contributions of CFI to Age-Related Macular Degeneration.

Perciliz L Tan, Melanie E Garrett, Jason R Willer, Peter A Campochiaro, Betsy Campochiaro, Donald J Zack, Allison E Ashley-Koch, Nicholas Katsanis

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Pathogenic variants inmedRxiv : the preprint server for health sciences · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Perciliz L TanCenter for Human Disease Modeling, Duke University Medical Center, Durham, North Carolina, United States 2Department of Cell Biology, Duke University Medical Center, Durham, North Carolina, United States.
Melanie E GarrettCenter for Human Disease Modeling, Duke University Medical Center, Durham, North Carolina, United States.
Jason R WillerCenter for Human Disease Modeling, Duke University Medical Center, Durham, North Carolina, United States.
Peter A CampochiaroDepartments of Ophthalmology, Neuroscience, Johns Hopkins School of Medicine, Baltimore, Maryland, United States.
Betsy CampochiaroDepartments of Ophthalmology, Neuroscience, Johns Hopkins School of Medicine, Baltimore, Maryland, United States.
Donald J ZackDepartments of Ophthalmology, Neuroscience, Johns Hopkins School of Medicine, Baltimore, Maryland, United States 4Center for Stem Cells and Ocular Regenerative Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, United States 5Department of Molecular Biology and Genetics, Johns Hopkins School of Medicine, Baltimore, Maryland, United States.
Allison E Ashley-KochCenter for Human Disease Modeling, Duke University Medical Center, Durham, North Carolina, United States 6Departments of Medicine, Molecular Genetics and Microbiology, Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina, United States.
Nicholas KatsanisCenter for Human Disease Modeling, Duke University Medical Center, Durham, North Carolina, United States 2Department of Cell Biology, Duke University Medical Center, Durham, North Carolina, United States.
Duke Medical Center · USJohns Hopkins Medicine · USDuke University Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Genome-wide association (GWAS) and sequencing studies for AMD have highlighted the importance of coding variants at loci that encode components of the complement pathway. However, assessing the contribution of such alleles to AMD, especially when they are rare, remains coarse, in part because of the persistent challenge in establishing their functional relevance. Others and we have shown previously that rare alleles in complement factor I (CFI) can be tested functionally using a surrogate in vivo assay of retinal vascularization in zebrafish embryos. Here, we have implemented and scaled these tools to assess the overall contribution of rare alleles in CFI to AMD. Methods: We performed targeted sequencing of CFI in 731 AMD patients, followed by replication in a second patient cohort of 511 older healthy individuals. Systematic functional testing of all alleles and post-hoc statistical analysis of functional variants was also performed. Results: We discovered 20 rare coding nonsynonymous variants, including the previously reported G119R allele. In vivo testing led to the identification of nine variants that alter CFI; six of which are associated with hypoactive complement factor I (FI). Post-hoc analysis in ethnically matched, population controls showed six of these to be present exclusively in cases. Conclusions: Taken together, our data argue that multiple rare and ultra-rare alleles in CFI contribute to AMD pathogenesis; they improve the precision of the assessment of the contribution of CFI to AMD; and they offer a rational route to establishing both causality and direction of allele effect for genes associated with this disorder.

Indexed as

Genetic Predisposition to DiseasePolymorphism, Single NucleotideAgedAged, 80 and overAllelesAnimalsComplement Factor IDNAFemaleGenome-Wide Association StudyGenotypeHumansMacular DegenerationMaleMiddle AgedZebrafishComplement Factor IDNA

Identifiers

PMID28282489
PMCPMC6022411
OpenAlexW2592132756

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.